Active clinical trials for "Behavior, Addictive"

the study aims to identify the effect of addiction on TIMI flow in patients presented with acute coronary syndrome. identify the effect of addiction on outcomes of medical treatment of patients presenting with acute coronary syndrome. identify the relation between addiction and LV function. detect the effect of duration of addiction on myocardial infarction lesion and outcomes of pci.

Sexual addiction, also known as hypersexuality or compulsive sexuality, is a human sexual behavior that results in a continuous and persistent search for sexual pleasure. Replacing the former terms satyriasis and nymphomania, the World Health Organization (WHO) ICD-11 has referred to this disorder as "compulsive sexual behavior disorders". From multiple causes (iatrogeny, neurological causes, psychiatric causes, psychopathological hypotheses), but still only partially known, the inclusion of this disorder among impulsivity-related disorders, obsessive-compulsive disorders or addiction-related disorders is still debated in the scientific literature. Thus, in the absence of sufficient robust scientific data, DSM-5 refused to include this disorder in its classification. However, the consequences of this disorder on the psychosocial functioning of individuals are not negligible, which can go as far as the precipitation of a transition to an heteroaggressive act which can thus lead to incarceration. The prevalence of this disorder in the general population is estimated between 2 and 6% based on current literature data. This rate appears to be higher among men and more specifically among sex offenders. However, some authors have noted that the difficulty in determining a clear prevalence of sexual addiction may be related to the still poorly defined diagnostic criteria for this disorder as well as the choice of measurement tools. In the inmate population, to our knowledge, there are no French prevalence studies of this disorder. In addition, no studies have been conducted to compare the prevalence of sexual addiction among sex offenders (SASO) with that among non-sex offenders (SANSO). We hope that better screening for addiction would enable better management of patients with this disorder, promoting their psychosocial rehabilitation and well-being, so as to prevent the recurrence of a transition to sexual arousal.

The use of crack-cocaine is growing at alarming rate in our country and it is absolutely worrisome the fast establishment of addiction to it. Its immediate effects, that are intense and extremely fleeting, increase dramatically the probability of this drug to be consumed again, settling quickly down the loss of control and the compulsive use, turning the effects of this drug highly addictive. Parallel to this process, brain damages are quickly established, progressing to severe impairments of frontal functions, leading to the lack of cognitive control that feeds back and aggravates the dependence, and hampers any therapeutic approach. The existing treatments have not proved to be satisfactory yet. Thus, considering that a new modality of treatment, based on the neuromodulation induced by noninvasive brain stimulation, has been useful in treating various neuropsychiatric conditions, this study will examine the potential beneficial effects of repeated transcranial Direct Current Stimulation over the left dorsolateral prefrontal cortex in the treatment of crack-cocaine addiction.

In this study, eligible crack-cocaine addicted inpatients recruited from specialized clinics for substance abuse disorder treatment, filling inclusion criteria and not showing any exclusion criteria, were randomized to receive the repetitive (10 sessions, every other day) bilateral dorsolateral Prefrontal Cortex (dlPFC: cathodal left / anodal right) tDCS (2 milliamperes, 3x7 cm2, for 20 min) or placebo (sham-tDCS). Craving to the use of crack-cocaine was examined before (baseline), during and after the end of the tDCS treatment. Based in our previous data, our hypothesis was that repetitive bilateral tDCS over dlPFC would favorably change clinical, cognitive and brain function in crack-cocaine addiction and these would be long-lasting effects.

The Sponsor is doing a research study to assess the effects of a smartphone program designed to help users smoke less and eventually quit. When participants join, their involvement in the core study will last 8 weeks. After 8 weeks, they will have the option to continue using the program to guide their quit journey or participate in follow-up research.

Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use. Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.

We propose that the systemic administration of lidocaine following the induction of cue-induced craving, relative to saline plus cue-induced craving or lidocaine without cue-induced craving, will block the reconsolidation of cue memories. This will lead to a reduction in cue-induced craving upon repeated testing as well as subsequent cocaine use and basal craving.

Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This is a 6-month, open-label, re-treatment study that will confirm the safety and efficacy of Probuphine in patients who have previously completed the 6-month PRO-806 study with either Probuphine, placebo or sublingual buprenorphine.

The purpose of this study is to assess the effects of an aerobic and strength training exercise program (one that increases the need for oxygen and increases muscle) on the treatment outcomes of 150 individuals in treatment for methamphetamine dependence at Cri-Help. The study will determine if a 60-minute exercise program (three times a week) has an effect (good or bad) on the health and drug use of participants as compared to individuals not participating in an exercise program.

This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.